Literature DB >> 34480921

The β-cell glucose toxicity hypothesis: Attractive but difficult to prove.

Gordon C Weir1, Peter C Butler2, Susan Bonner-Weir3.   

Abstract

β cells in the hyperglycemic environment of diabetes have marked changes in phenotype and function that are largely reversible if glucose levels can be returned to normal. A leading hypothesis is that these changes are caused by the elevated glucose levels leading to the concept of glucose toxicity. Support for the glucose toxicity hypothesis is largely circumstantial, but little progress has been made in defining the responsible mechanisms. Then questions emerge that are difficult to answer. In the very earliest stages of diabetes development, there is a dramatic loss of glucose-induced first-phase insulin release (FPIR) with only trivial elevations of blood glucose levels. A related question is how impaired insulin action on target tissues such as liver, muscle and fat can cause increased insulin secretion. The existence of a sophisticated feedback mechanism between insulin secretion and insulin action on peripheral tissues driven by glucose has been postulated, but it has been difficult to measure increases in blood glucose levels that might have been expected. These complexities force us to challenge the simplicity of the glucose toxicity hypothesis and feedback mechanisms. It may turn out that glucose is somehow driving all of these changes, but we must develop new questions and experimental approaches to test the hypothesis.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glucose toxicity; Insulin; Insulin secretion; beta cells

Mesh:

Substances:

Year:  2021        PMID: 34480921      PMCID: PMC8530963          DOI: 10.1016/j.metabol.2021.154870

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  99 in total

1.  Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance.

Authors:  Yasuo Terauchi; Iseki Takamoto; Naoto Kubota; Junji Matsui; Ryo Suzuki; Kajuro Komeda; Akemi Hara; Yukiyasu Toyoda; Ichitomo Miwa; Shinichi Aizawa; Shuichi Tsutsumi; Yoshiharu Tsubamoto; Shinji Hashimoto; Kazuhiro Eto; Akinobu Nakamura; Mitsuhiko Noda; Kazuyuki Tobe; Hiroyuki Aburatani; Ryozo Nagai; Takashi Kadowaki
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

2.  Age Mosaicism across Multiple Scales in Adult Tissues.

Authors:  Rafael Arrojo E Drigo; Varda Lev-Ram; Swati Tyagi; Ranjan Ramachandra; Thomas Deerinck; Eric Bushong; Sebastien Phan; Victoria Orphan; Claude Lechene; Mark H Ellisman; Martin W Hetzer
Journal:  Cell Metab       Date:  2019-06-06       Impact factor: 27.287

3.  Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons.

Authors:  D K McCulloch; D J Koerker; S E Kahn; S Bonner-Weir; J P Palmer
Journal:  Diabetes       Date:  1991-06       Impact factor: 9.461

4.  Effects of hemipancreatectomy on pancreatic alpha and beta cell function in healthy human donors.

Authors:  E R Seaquist; R P Robertson
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

5.  Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study.

Authors:  Adam G Tabák; Markus Jokela; Tasnime N Akbaraly; Eric J Brunner; Mika Kivimäki; Daniel R Witte
Journal:  Lancet       Date:  2009-06-08       Impact factor: 79.321

6.  Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats.

Authors:  J L Leahy; L M Bumbalo; C Chen
Journal:  Diabetes       Date:  1994-02       Impact factor: 9.461

7.  Pancreatic beta-cell mass in European subjects with type 2 diabetes.

Authors:  J Rahier; Y Guiot; R M Goebbels; C Sempoux; J C Henquin
Journal:  Diabetes Obes Metab       Date:  2008-11       Impact factor: 6.577

8.  Biphasic dynamics of beta cell mass in a mouse model of congenital hyperinsulinism: implications for type 2 diabetes.

Authors:  Sharona Tornovsky-Babeay; Noa Weinberg-Corem; Rachel Ben-Haroush Schyr; Dana Avrahami; Judith Lavi; Eseye Feleke; Klaus H Kaestner; Yuval Dor; Benjamin Glaser
Journal:  Diabetologia       Date:  2021-02-09       Impact factor: 10.122

9.  Palmitate is not an effective fuel for pancreatic islets and amplifies insulin secretion independent of calcium release from endoplasmic reticulum.

Authors:  Iok Teng Kuok; Austin M Rountree; Seung-Ryoung Jung; Ian R Sweet
Journal:  Islets       Date:  2019-05-14       Impact factor: 2.694

Review 10.  Hypoxia signaling in human diseases and therapeutic targets.

Authors:  Jae W Lee; Junsuk Ko; Cynthia Ju; Holger K Eltzschig
Journal:  Exp Mol Med       Date:  2019-06-20       Impact factor: 8.718

View more
  4 in total

Review 1.  Alpha-to-beta cell trans-differentiation for treatment of diabetes.

Authors:  Mohamed Saleh; George K Gittes; Krishna Prasadan
Journal:  Biochem Soc Trans       Date:  2021-12-17       Impact factor: 5.407

Review 2.  Molecular Mechanism of Pancreatic β-Cell Failure in Type 2 Diabetes Mellitus.

Authors:  Hideaki Kaneto; Tomohiko Kimura; Masashi Shimoda; Atsushi Obata; Junpei Sanada; Yoshiro Fushimi; Taka-Aki Matsuoka; Kohei Kaku
Journal:  Biomedicines       Date:  2022-03-31

3.  High Prevalence of Abnormal Carcinoembryonic Antigen in Diabetic Inpatients with Poor Glycemic Control.

Authors:  Xi-Yu Liu; Chai Jin; Yan Zhou
Journal:  Diabetes Metab Syndr Obes       Date:  2022-08-04       Impact factor: 3.249

4.  Hepatic Steatosis and High-Normal Fasting Glucose as Risk Factors for Incident Prediabetes.

Authors:  Toru Aizawa; Yasuto Nakasone; Norimitsu Murai; Rie Oka; Shoichiro Nagasaka; Koh Yamashita; Takahiro Sakuma; Kendo Kiyosawa
Journal:  J Endocr Soc       Date:  2022-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.